Racial variation in breast tumor promoter methylation in the carolina breast cancer study

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 6, 2015, Pages 921-930

  Conway, Kathleen ^a,b   Edmiston, Sharon N ^b   Tse, Chiu Kit ^a   Bryant, Christopher ^a   Kuan, Pei Fen ^c   Hair, Brionna Y ^a   Parrish, Eloise A ^b   May, Ryan ^d   Swift Scanlan, Theresa ^b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Stony Brook University   (United States)

^d EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; AXL GENE; BREAST CANCER; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNAJC15 GENE; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HBII 52 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MENOPAUSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; SIGNAL TRANSDUCTION; TES GENE; TUSC3 GENE; AFRICAN AMERICAN; ANCESTRY GROUP; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; CAUCASIAN; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; EPIDEMIOLOGY; ETHNOLOGY; FOLLOW UP; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; NORTH CAROLINA; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

AFRICAN AMERICANS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NORTH CAROLINA; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84941773224     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1228     Document Type: Article

References (48)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-18.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-52.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
5. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe H, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Physicians 2006;56:168-83.
6. Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Womens Health 2011;7:677-87.
7. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002;94:334-57.
8. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100-10.
9. Herman JG. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol 2005;70:329-33.
10. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol 2011;5:77-92.
11. Dumitrescu RG, Marian C, Krishnan SS, Spear SL, Kallakury BVS, Perry DJ, et al. Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med 2010;14:1468-75.
12. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang B, et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010;16: 3539-47.
13. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS ONE 2012;7:e37928.
14. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, et al. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 2004;10:2052-7.
15. Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, et al. Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 2014;5:237-48.
16. Newman B,Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, et al. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 1995;35:51-60.
17. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 2010;31:1417-23.
18. Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, et al. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res 2014;16:450.
19. Byun HM, Siegmund KD, Pan F,Weisenberger DJ, Kanel G, Laird PW, et al. Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue-and individual-specific DNA methylation patterns. Hum Mol Genet 2009;18:4808-17.
20. Wedderburn, Robert WM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974;61:439-47.
21. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
22. Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat 2013;142: 365-80.
23. Heyn H, Moran S, Hernando-Herraez I, Sayols S,GomezA, Sandoval J, et al. DNA methylation contributes to natural human variation. Genome Res 2013;23:1363-72.
24. Thomas N E, Slater NA, Edmiston SN, Zhou X, Kuan PF, Groben PA, et al. DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res 2014;27:1097-1105.
25. Xu S, Wang Y, Roe B, Pearson WR. Characterization of the human class Mu glutathione S-transferase gene cluster and theGSTM1 deletion. J Biol Chem 1998;273:3517-27.
26. Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011;5:61-76.
27. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011;71: 6195-207.
28. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.
29. Koestler DC, Christensen B, Karagas MR,Marsit CJ, Langevin SM,KelseyKT, et al. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics 2013;8:816-26.
30. Zhang X, Moen EL, Liu C, Mu W, Gamazon ER, Delaney SM, et al. Linking the genetic architecture of cytosine modifications with human complex traits. Hum Mol Genet 2014;23:5893-905.
31. Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome.Genome Res 2010;20:883-9.
32. Moen EL, Zhang X,MuW, Delaney SM, Wing C, McQuade J, et al. Genomewide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics 2013;194: 987-96.
33. Terry MB, Ferris JS, Pilsner R, Flom JD, Tehranifar P, Santella RM, et al. GenomicDNAmethylation amongwomen in a multiethnicNewYork City birth cohort. Cancer Epidemiol. Biomarkers Prev 2008;17:2306-10.
34. Adkins RM, Krushkal J, Tylavsky FA, Thomas F. Racial differences in genespecific DNA methylation levels are present at birth. Birth Defects Research Part A. Clin Mol Teratol 2011;91:728-36.
35. Fang WK, Gu W, Li EM, Wu ZY, Shen ZY, Shen JH, et al. Reduced membranous and ectopic cytoplasmic expression of DSC2 in esophageal squamous cell carcinoma: an independent prognostic factor. Hum Pathol 2010;41:1456-65.
36. Hamidov Z, Altendorf-Hofmann A, Chen Y, Settmacher U, Petersen I, Knösel T. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol 2011;64:990-4.
37. Culhane AC, Quackenbush J. Confounding effects in "A six-gene signature predicting breast cancer lung metastasis". Cancer Res 2009;69:7480-5.
38. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993;85: 1159-64.
39. Tobias ES, Hurlstone AF, MacKenzie E, McFarlane R, Black DM. The TES gene at 7q31.1 is methylated in tumours and encodes a novel growthsuppressing LIM domain protein. Oncogene 2001;20:2844-53.
40. Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG, et al. Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci 2012;103: 2092-101.
41. Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, et al. Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer 2013;119: 946-54.
42. Choufani S, Shapiro JS, Susiarjo M, Butcher DT, Grafodatskaya D, Lou Y, et al. A novel approach identifies new differentially methylated regions (DMRs) associated with imprinted genes. Genome Res 2011;21:465-76.
43. Breton CV, Salam MT, Gilliland FD. Heritability and role for the environment in DNA methylation in AXL receptor tyrosine kinase. Epigenetics 2011;6:895-8.
44. Gjerdrum C, TironC, Høiby T, Stefansson I, HaugenH, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-9.
45. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 2006;103:5799-804.
46. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 2008;28:161-76.
47. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobaccosmoke exposure affects global and gene-specificDNAmethylation. Am J Respir Crit Care Med 2009;180:462-7.
48. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121: 2750-67.